Home » Newsletters » BioWorld Science

BioWorld Science

April 16, 2015

View Archived Issues

New murine models of autosomal dominant temporal lobe epilepsy

Periostin shows promise as a differential diagnostic marker

Novel thienopyrimidinone PDE7 inhibitors discovered at Kaken

New role suggested for Nkx-3.1 as a biomarker in male breast carcinoma

Health Canada clears Hydra to begin phase I study of HX-100

Merck & Co. presents novel MR antagonists

Godavari Biorefineries discloses novel antineoplastics

Shanghai Yingli patents new PI3Kdelta inhibitors

Theravectys gains exclusive license to Institut Curie's library of synthetic humanized nanobodies

RegImmune, JDRF and Pfizer team up to develop antigen-specific immunotherapy for type 1 diabetes

Identification of a selective, small-molecule DYRK1A inhibitor

MSD and Astellas Pharma combine forces against type 2 diabetes in Japan

Primary endpoint met in phase IIb trial of JAK1 inhibitor for rheumatoid arthritis

Effimune gets go-ahead for phase I trial of immunomodulatory antibody

Critical Path Institute's skeletal muscle safety markers supported by regulatory agencies

Compugen gains rights to use NIH biological systems and materials

FDA advisory committee says alogliptin, saxagliptin have acceptable CV risk profiles

Novel biomarkers for neuroendocrine tumors

Roche and Genentech patent CDK8 inhibitors

University of Basel and PIQUR Therapeutics disclose PI3Kalpha/mTOR nhibitors

Bayer Schering Pharma patents FXIa inhibitors

FDA sets review action date for Repros' enclomiphene citrate NDA

FDA advisory committee recommends approval of cangrelor for use in PCI

FDA approves Amgen's ivabradine for chronic heart failure

Active Biotech and Ipsen discontinue development of tasquinimod for prostate cancer

BMS and Lexicon select neuropathic pain candidate

Senju licenses Asian rights to Eyenovia ophthalmic delivery technology

China FDA clears IND for development of DP-VPA through phase III for epilepsy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...